Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276–83.

Article  PubMed  Google Scholar 

Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575–628.

Article  PubMed  Google Scholar 

Sheppard JD, Nichols KK. Dry eye disease associated with meibomian gland dysfunction: focus on tear film characteristics and the therapeutic landscape. Ophthalmol Ther. 2023;12(3):1397–418.

Article  PubMed  PubMed Central  Google Scholar 

Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017;15(3):334–65.

Article  PubMed  Google Scholar 

Wrobel-Dudzinska D, Osial N, Stepien PW, et al. Prevalence of dry eye symptoms and associated risk factors among university students in Poland. Int J Environ Res Public Health. 2023;20(2):1313.

Article  PubMed  PubMed Central  Google Scholar 

Barabino S, Benitez-Del-Castillo JM, Fuchsluger T, et al. Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification. Eur Rev Med Pharmacol Sci. 2020;24(17):8642–52.

CAS  PubMed  Google Scholar 

Sabeti S, Kheirkhah A, Yin J, et al. Management of meibomian gland dysfunction: a review. Surv Ophthalmol. 2020;65(2):205–17.

Article  PubMed  Google Scholar 

Mukamal R. Improved dry eye drugs for 2022 and beyond. 2021. https://www.aao.org/eye-health/tips-prevention/new-dry-eye-treatments-ocular-surface-disease. Accessed 27 Feb 2024.

US Food and Drug Administration. MIEBO (perfluorohexyloctane ophthalmic solution) for topical ophthalmic use: US prescribing information. 2024. https://dailymed.nlm.nih.gov/dailymed. Accessed 27 Feb 2024.

Agarwal P, Scherer D, Günther B, et al. Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs. Int J Pharm. 2018;538(1–2):119–29.

Article  CAS  PubMed  Google Scholar 

Tsagogiorgas C, Otto M. Semifluorinated alkanes as new drug carriers-an overview of potential medical and clinical applications. Pharmaceutics. 2023;15(4):1211.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tauber J, Wirta DL, Sall K, et al. A randomized clinical study (SEECASE) to assess efficacy, safety, and tolerability of NOV03 for treatment of dry eye disease. Cornea. 2021;40(9):1132–40.

Article  PubMed  Google Scholar 

Liu X, Riess J, Krafft M. Self-organization of semifluorinated alkanes and related compounds at interfaces: thin films, surface domains and two-dimensional spherulites. Bull Chem Soc Jpn. 2018;91(5):846–57.

Article  CAS  Google Scholar 

Krösser S, Spencer E, Grillenberger R, et al. Ocular and systemic distribution of 14C- perfluorohexyloctane following topical ocular administration to rabbits [abstract no. 2656 plus poster]. Invest Ophthalmol Vis Sci. 2018;59(9):2656.

Schmidl D, Bata AM, Szegedi S, et al. Influence of perfluorohexyloctane eye drops on tear film thickness in patients with mild to moderate dry eye disease: a randomized controlled clinical trial. J Ocul Pharmacol Ther. 2020;36(3):154–61.

Article  CAS  PubMed  Google Scholar 

Steven P, Augustin AJ, Geerling G, et al. Semifluorinated alkane eye drops for treatment of dry eye disease due to meibomian gland disease. J Ocul Pharmacol Ther. 2017;33(9):678–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Borchman D, Vittitow J, Kissling R, et al. Spectroscopic characterization of perfluorohexyloctane, an eye drop for dry eye disease [abstract no. 3975-B0292 plus poster]. Invest Ophthalmol Vis Sci. 2023;64(8):3975.

Stolowich N, Vittitow J, Kissling R, et al. Oxygen-carrying capacity of perfluorohexyloctane, a novel eye drop for dry eye disease. Curr Ther Res Clin Exp. 2023;98(100705):1–5.

Google Scholar 

Agarwal P, Khun D, Krösser S, et al. Preclinical studies evaluating the effect of semifluorinated alkanes on ocular surface and tear fluid dynamics. Ocul Surf. 2019;17(2):241–9.

Article  PubMed  Google Scholar 

Steven P, Scherer D, Krösser S, et al. Semifluorinated alkane eye drops for treatment of dry eye disease-a prospective, multicenter noninterventional study. J Ocul Pharmacol Ther. 2015;31(8):498–503.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vittitow J, Kissling R, DeCory H, et al. In vitro inhibition of evaporation with perfluorohexyloctane, an eye drop for dry eye disease. Curr Ther Res Clin Exp. 2023;98(100704):1–7.

Google Scholar 

Delicado-Miralles M, Velasco E, Díaz-Tahoces A, et al. Deciphering the action of perfluorohexyloctane eye drops to reduce ocular discomfort and pain. Front Med (Lausanne). 2021. https://doi.org/10.3389/fmed.2021.709712.

Article  PubMed  PubMed Central  Google Scholar 

Borchman D, Cavet M, DeCory H, et al. Visualization of perfluorohexyloctane, an eye drop for dry eye disease, on the human ocular surface using infrared emissivity [poster]. Annual meeting of the American Academy of Ophthalmology. 2023.

Tauber J, Berdy GJ, Wirta DL, et al. NOV03 for dry eye disease associated with meibomian gland dysfunction: results of the randomized phase 3 GOBI study. Ophthalmology. 2023;130(5):516–24.

Article  PubMed  Google Scholar 

Sheppard JD, Kurata F, Epitropoulos AT, et al. NOV03 for signs and symptoms of dry eye disease associated with meibomian gland dysfunction: the randomized phase 3 MOJAVE study. Am J Ophthalmol. 2023;252:265–74.

Article  CAS  PubMed  Google Scholar 

Protzko EE, Segal BA, Korenfeld MS, et al. Long-term safety and efficacy of perfluorohexyloctane ophthalmic solution for the treatment of patients with dry eye disease: the KALAHARI Study. Cornea. 2023. https://doi.org/10.1097/ICO.0000000000003418.

Fahmy A, Evans D, Harthan J, et al. Perfluorohexyloctane (NOV03) for dry eye disease associated with meibomian gland dysfunction: pooled analysis of GOBI and MOJAVE studies [poster]. Annual Meeting of the American Optometric Association. 2023.

Groß D, Kaercher T. Comparison of the clinical efficacy of three different eye drops for the treatment of dry eye. EC Ophthalmol. 2021;12(6):32–44.

Google Scholar